Phosphodiesterase 5형 억제제의 부작용이 약물 선택에 미치는 영향
The Influence of Treatment-emergent Adverse Reactions on Selecting Phosphodiesterase Type 5 Inhibitors
양철수, 김세철,
소속 상세정보
양철수 ( Yang Chul-Soo )
중앙대학교 의과대학 비뇨기과학교실
김세철 ( Kim Sae-Chul )
중앙대학교 의과대학 비뇨기과학교실
KMID : 0358320060470030272
Abstract
Purpose: This study was conducted to determine how treatment-emergent adverse reactions(ARs) of each of the phosphodiesterase type 5 inhibitors (PDE5Is) influenced the patient when selecting a drug.
Materials and Methods: For our study, we recruited a total of 123 patients who were suffering with erectile dysfunction and they randomly took 3 different PDE5Is(sildenafil, tadalnafil, and vardenafil), at least 4 times each and then had successful intercourse after using each PDE5I. We investigated the influence of the treatment-emergent ARs on the patients selecting a PDE5I.
Results: Sixty eight out of 123 patients(55.3%) showed more than one AR. Five patients(4.1%) did not select any of the PDE5Is due to their treatment-emergent ARs, and 15 patients(12.2%) did not select the PDE5Is due to the severity and/or duration of the AR. Facial flushing was the most common cause of non-selection; this was followed by headache. Fifteen patients(12.2%) selected one specific PDE5I because they experienced a less severe AR with that drug. The severity and duration of the ARs increased in the group of elderly men and the group of men who took larger doses of the drug.
Conclusion: ARs had an important effect on the patients’ selection of a PDE5I, although the impact was quite low compared with its overall occurrence rate. The severity and/or duration of the AR were so variable, depending on the patient, that no PDE5I was better than the others in terms of attributing the selection of a PDE5I to its reduced AR. (Korean J Urol 2006;47:272-278)
키워드
Phosphodiesterase 5;Adverse drug reaction reporting systems
원문 및 링크아웃 정보
등재저널 정보